Medical treatment of functional XXXX .

@entity1 @entity2013 @entity7961 @entity935 @entity5 @entity699 @entity2012 @entity701 @entity977 @entity1943 @entity652
Medical therapy with a @entity935 agonist is the most effective for treatment of a prolactin-producing @entity652 and is considered as primary treatment. Surgery and pituitary radiation are reserved for @entity1 who either do not tolerate or do not respond to a @entity935 agonist drug. A @entity1943 analogue is effective medical therapy for @entity1 with @entity2012 , and this is usually administered if there is persistent GH hypersecretion after surgical resection. Medical treatment for @entity1 with @entity699 is directed at the adrenal glands to reduce @entity701 hypersecretion. Unfortunately, there is no effective medical therapy to reduce pituitary corticotropin production. Medical therapy for a @entity652 with a @entity935 agonist or @entity1943 analogue has limited utility but is employed in @entity1 who are unable to undergo surgery and may delay or prevent additional @entity5 growth. Many @entity1 with a @entity977 can be successfully treated with one treatment, either a @entity935 agonist for a @entity2013 or surgery for other types of @entity5 . A substantial number of @entity1 require multimodality therapy, however, including medical therapy, surgery, and pituitary radiation. Because the biologic behavior of pituitary @entity652 varies considerably, a @entity1 with a @entity977 requires lifelong regular monitoring for hormone hypersecretion, @entity5 recurrence, and development of new @entity7961 . A coordinated plan of care among endocrinologists, neurosurgeons, neuroophthalmologists, and radiation therapists is necessary to provide optimal care for these @entity1 .
